Day 1 | Day 2 | Download Brochure 

TUESDAY, JUNE 5

7:15 am Registration & Morning Coffee

EARLY ASSESSMENTS:
ASSAYS, MODELS AND MARKERS 

8:30 Chairperson’s Opening Remarks

Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories

8:40 Cellular QT Screens - Probing Adult Cardiac Myocytes

Lars Kaestner, Ph.D., Principal Investigator, Institute for Molecular Cell Biology, Saarland University

9:10 Evaluation of Cellular Impedance Measures of Cardiomyocyte Cultures for Drug Screening Applications

Matthew Peters, Ph.D., Principal Scientist, Safety Assessment, Astrazeneca

9:40 The Tell Tale Heart: Integration of Whole Heart Energetics, Proteomics, and Function to Assess Cardiac Toxicity in the Isolated Heart

Brian Roche, Ph.D., Cardiovascular Safety Pharmacologist, Safety Pharmacology, Battelle Memorial Institute

10:10 Coffee Break

10:40 Cardiac Contractility: Challenges in De-Risking

Jonathan Heyen, Ph.D., Principal Scientist, Global Safety Pharmacology, Pfizer Global Research & Development

11:10 Translating Cardiotoxicity: Can Stem Cells “Swim” Like Humans?

Gary Gintant, Ph.D., Senior Group Leader, Department of Integrative Pharmacology, Global Pharmaceutical Research & Development, Abbott Laboratories;

11:40 Use of Induced Pluripotent Stem Cell-Derived Cardiomyocytes to Understand Mechanisms of Cardiotoxicity

Dinesh Puppala, Ph.D., Senior Scientist, Compound Safety Prediction Group, Pfizer, Inc.

Sponsored by
12:10 pm Sponsored Presentation

Speaker to be Announced

12:25 pm Luncheon Presentation (Sponsorship Opportunity Available) or Lunch on Your Own

1:10 Session Break

New Insights Into The Role Of Ion Channels 

1:30 Chairperson’s Remarks

Peter Hoffmann, M.D., Ph.D., Executive Director, Preclinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation

1:40 Cardiac Sodium Channel Inhibition: A Risk Marker During Early Drug Development

Peter Hoffmann, M.D., Ph.D., Executive Director, Pre-Clinical Safety and Translational Cardiovascular Advisory Team, Novartis Pharmaceuticals Corporation

2:10 What is New About hERG Channel Inhibition? Atypical hERG Inhibition and Mitigation Strategies

Gul Erdemli, M.D., Ph.D., DABT, Head, Ion Channel Group, Novartis Institutes for BioMedical Research, Inc.

2:40 Regional Genomic Regulation of Cardiac Ion Channels by Estrogen and its Implications to Sex Differences in Arrhythmia Risk

Guy Salama, Ph.D., Professor, Department of Medicine, University of Pittsburgh, School of Medicine

Sponsored by
3:10 Translational Cardiovascular Safety:
Optimizing the Integration of Pre-Clinical and Clinical Safety Data

Sarah S. Bacus, Ph.D., CSO & Senior Vice President, Innovation, Quintiles Pacific, Inc.

3:40 Refreshment Break in the Exhibit Hall with Poster Viewing

4:40 Interactive Discussion Groups

Concurrent problem-solving discussions on specific topics, to provide a forum for exchanging ideas, voicing opinions and meeting potential collaborators. Discussions will be led by a moderator/s, limited to 15 participants per table, and open to all attendees and exhibitors.

5:40 Welcome Reception in the Exhibit Hall with Poster Viewing

6:45 End of Day

Day 1 | Day 2 | Download Brochure